P

PharmaCyte Biotech, Inc. (PMCB)

NCM – Real vaqt narxi. Valyuta: USD

0.79

+0.10 (13.69%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

P

PharmaCyte Biotech, Inc. (PMCB)

NCM – Real vaqt narxi. Valyuta: USD

0.79

+0.10 (13.69%)

Yopilishda: May 12, 2026, 4:00 PM EDT

25.11.2025

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further validating the Company's strategic approach to capital deployment and strengthening its already solid financial position. Following the monetization of the stake, PharmaCyte's cash and marketable securities are expected to increase to approximately $20 million, up from $13.3 million as of July 31, 202.

Videolar

No Data

There is no data to display

Press-relizlar

25.11.2025

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further validating the Company's strategic approach to capital deployment and strengthening its already solid financial position. Following the monetization of the stake, PharmaCyte's cash and marketable securities are expected to increase to approximately $20 million, up from $13.3 million as of July 31, 202.

Search stocks

PharmaCyte Biotech, Inc. (PMCB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

PharmaCyte Biotech, Inc. (PMCB)

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

Videolar

No Data

Press-relizlar

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment